Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial - Das, Sunit; Sahgal, Arjun; Perry, James R. (Frontiers in Oncology, 2020)